ืžื—ืงืจื™ื ื‘ื ื•ืฉื ื”ืฉื™ืžื•ืฉ ื‘-PRP ืœื˜ื™ืคื•ืœ ื‘ื ืฉื™ืจืช ืฉื™ืขืจ

ื˜ื™ืคื•ืœ PRP ื ื—ืฉื‘ ื›ื‘ืจ ืฉื ื™ื ืœืื—ื“ ื”ื˜ื™ืคื•ืœื™ื ื”ื—ื“ืฉื ื™ื™ื, ื”ืคืฉื•ื˜ื™ื ื•ื™ืขื™ืœื™ื ืœืฆื•ืจืš ืฉื™ืงื•ื ืฉื™ืขืจ ื”ืŸ ืœืคื ื™ ื”ืฉืชืœืช ืฉื™ืขืจ, ืœืื—ืจื™ื” ื•ืœืฆื•ืจืš ืฉื™ืงื•ื ื”ืฉื™ืขืจ ื’ื ืœืœื ื”ืฉืชืœืช ืฉื™ืขืจ. ืจื‘ื™ื ืฉื•ืืœื™ื ืื•ืชื™ ืื ืงื™ื™ื ืžื—ืงืจ ื‘ื ื•ืฉื PRP ื›ืš ืฉื™ื•ื›ืœื• ืœืœืžื•ื“ ืžืžื ื• ืขืœ ื”ืชื•ืขืœืช ื”ื ื•ื‘ืขืช ืžื”ื˜ื™ืคื•ืœ.

ื‘ืžื”ืœืš ื˜ื™ืคื•ืœ PRP, ื ืœืงื— ื“ื ืžื”ืžื˜ื•ืคืœ, ืžื•ืขื‘ืจ ื‘ืฆื ื˜ืจื™ืคื•ื’ื” ืœืฆื•ืจืš ื–ื™ืงื•ืง ืคืœื–ืžื” ืขืฉื™ืจื” ื‘ื˜ืกื™ื•ืช. ื”ืจื™ื›ื•ื– ื”ื’ื‘ื•ื”ื” ืฉืœ ื”ื˜ืกื™ื•ืช, ื”ื’ื‘ื•ื”ื” ื‘ื›ืคื™ 5 ืžื”ืจื™ื›ื•ื– ื”ืงื™ื™ื ื‘ืื•ืคืŸ ื˜ื‘ืขื™ ื‘ื“ื, ืžืืคืฉืจ ื—ื™ื“ื•ืฉ ืขื•ืจ ื”ืงืจืงืคืช ื•ืžืืคืฉืจ ื”ื’ื‘ืจืช ืฆืžื™ื—ืช ืฉื™ืขืจ.

ืžื—ืงืจื™ื ืจื‘ื™ื ืžืฆืื• ื›ื™ ื’ื•ืจืžื™ ื”ื’ื“ื™ืœื” ื”ืžืฆื•ื™ื™ื ื‘ื˜ืกื™ื•ืช ืžื•ื ืขื™ื ื ื™ื•ื•ืŸ ื•ืžื—ื™ื™ื ืืช ื–ืงื™ืงื™ ื”ืฉื™ืขืจ, ื”ืฉื™ืžื•ืฉ ื‘-PRP ืžืืคืฉืจ ื™ืฆื™ืจื” ืฉืœ ื›ืœื™ ื“ื ื—ื“ืฉื™ื ื•ื‘ื›ืš ืžืฉืคืจ ืืช ื–ืจื™ืžืช ื”ื“ื ืœืจืงืžื”.

ื›ืžื• ื›ืŸ, ื”ืฉื™ืžื•ืฉ ื‘-PRP ืงื™ื™ื ื›ื‘ืจ ืฉื ื™ื ืœืฆื•ืจืš ื˜ื™ืคื•ืœ ื‘ื‘ืขื™ื•ืช ืื•ืจืชื•ืคื“ื™ื•ืช ื›ืžื•ย PRP ืœื›ืชืฃย ืื•ย PRP ืœื‘ืจืš, ืจื™ืคื•ื™ ืคืฆืขื™ื ืงืฉื™ื™ ืจื™ืคื•ื™, ื˜ื™ืคื•ืœื™ ืฉื™ื ื™ื™ื,ย ื˜ื™ืคื•ืœ ืขืจืคื“ย ื•ื›ื•ืณ.

ื‘ื“ืฃ ื–ื” ืื ื• ื ื“ื•ืŸ ื‘ืžืงื‘ืฅ ืงื˜ืŸ ืฉืœ ืžื—ืงืจื™ื ืฉื‘ื•ืฆืขื• ื‘ืžื”ืœืš ื”ืฉื ื™ื, ื›ืžื• ื›ืŸ, ื ื“ื•ืŸ ื‘ืžื—ืงืจื™ื ื”ืžืฉื•ื•ื™ื ื‘ื™ืŸ PRP ืœ-PRF. ื™ืฉ ืœื”ื“ื’ื™ืฉ ื›ื™ ืฉื ื™ ื”ื˜ื™ืคื•ืœื™ื ืžื•ืฆืขื™ื ื‘ืžืจืคืื” ื•ืœืขืชื™ื ื’ื ืžืชื‘ืฆืข ืฉื™ืœื•ื‘ ืฉืœ ื”ืฉื ื™ื™ื.

ื‘ืžื—ืงืจ ืžืฉื ืช 2016 ืฉืœ Alves et al. ืžืกืคืจื“:

ืžื—ืงืจ double-blind ื–ื” ื”ืชื‘ืฆืข ืขืœ 25 ืžื˜ื•ืคืœื™ื, ืชื•ืš ื‘ืงืจื” ืขื ืคืœืกื‘ื•. ื”ื•ื–ืจืง ืœื—ืฆื™ ืžืจืืฉื ืฉืœ ื”ืžื˜ื•ืคืœื™ื PRP ื•ืœื—ืฆื™ื• ื”ืฉื ื™ ืคืœืกื‘ื•. ื‘ื•ืฆืข ื˜ื™ืคื•ืœ ืื—ื“ ื›ืœ ื—ื•ื“ืฉ, 3 ื˜ื™ืคื•ืœื™ื ื‘ืกืš ื”ื›ืœ. ืชื•ืฆืื•ืช ืžื—ืงืจ ื–ื” ื’ื™ืœื• ื›ื™ ืžืชืŸ PRP ื”ื•ื‘ื™ืœ ืœืขืœื™ื™ื” ืžื•ื‘ื”ืงืช ืกื˜ื˜ื™ืกื˜ื™ืช ื‘ืื—ื•ื– ืฉืขืจื•ืช ื”ืื ืื’ืŸ ื”ืžืžื•ืฆืขื•ืช, ื™ืจื™ื“ื” ื‘ืฉืขืจื•ืช ื”ื˜ืœื•ื’ื ื™ื•ืช ื•ืขืœื™ื” ื‘ืฆืคื™ืคื•ืช ื”ืฉื™ืขืจ ืœืื—ืจ 3 ื—ื•ื“ืฉื™ื ื•ืื—ืจื™ 6 ื—ื•ื“ืฉื™ื ื‘ื”ืฉื•ื•ืื” ืœื‘ืกื™ืก.ย ืœืงืจืื™ืช ื”ืžื—ืงืจ ืœื—ืฅ ื›ืืŸ.

ื‘ืžื—ืงืจ ืžืฉื ืช 2015 ืฉืœ Singhal et al. ืžื”ื•ื“ื•:

ื‘ืžื—ืงืจ ื–ื” ื”ืชืžืงื“ื• ื‘ืžื‘ื—ืŸ ืฉื ืงืจื hair pull test ืื• ื‘ืคื™ืจื•ืฉ ื—ื•ืคืฉื™, ืดื‘ื“ื™ืงืช ืžืฉื™ื›ืช ืฉื™ืขืจืด, ื”ืžื‘ื—ืŸ ื‘ื•ืฆืข ืขืœ ื’ื‘ืจื™ื ื•ื ืฉื™ื, 3 ืคืขืžื™ื ืขืœ ื™ื“ื™ ืื•ืชื• ืจื•ืคื, ื›ืืฉืจ ืฆืจื•ืจ ืฉืœ ื›-50-60 ืฉื™ืขืจ ื ืชืคืก ื‘ื™ืŸ ื”ืื’ื•ื“ืœ, ื”ืืฆื‘ืข ื”ืžื•ืจื” ื•ื”ืืฆื‘ืข ื”ืืžืฆืขื™ืช ืžื”ื‘ืกื™ืก ืงืจื•ื‘ ืœืงืจืงืคืช. ื”ืฉื™ืขืจ ื ืžืฉืš ื‘ื—ื•ื–ืงื” ืžื”ืงืจืงืคืช, ื•ื”ืฉื™ืขืจ ืฉื ืชืœืฉ ื ืกืคืจ ื‘ื›ืœ ืžืคื’ืฉ. ื›ื“ื™ ืœื”ืขืจื™ืš ืืช ืฆืžื™ื—ืช ื”ืฉื™ืขืจ ื”ื›ื•ืœืœืช, ื ืคื— ื”ืฉื™ืขืจ, ืื™ื›ื•ืช ื”ืฉื™ืขืจ ื•ืžืœืื•ืช ื”ืฉื™ืขืจ, ืชืžื•ื ื•ืช ื’ืœื•ื‘ืœื™ื•ืช ื ืœืงื—ื•ืช ื‘ื›ืœ ืžืคื’ืฉ ืžื”ืชืฆื•ื’ื” ื”ืงื“ืžื™ืช, ื”ืงื•ื“ืงื•ื“ื™ืช, ื”ืฆื™ื“ื™ืช ื•ื”ืื—ื•ืจื™ืช. ืชื•ืฆืื•ืช ื”ืžื—ืงืจ ื”ื™ื• ืžืื“ ืžืขื•ื“ื“ื•ืช: ืฆืžื™ื—ืช ืฉื™ืขืจ ื ืจืืชื” ื‘ืฉื™ืฉื” ืžื˜ื•ืคืœื™ื ืœืื—ืจ 7 ื™ืžื™ื ื•ื‘ืืจื‘ืขื” ืžื˜ื•ืคืœื™ื ืœืื—ืจ 15 ื™ื•ื. ื‘ืชื•ื 3 ื—ื•ื“ืฉื™ื, ืœื›ืœ ื”ืžื˜ื•ืคืœื™ื ื”ื™ื™ืชื” ืฆืžื™ื—ืช ืฉื™ืขืจ ื˜ื•ื‘ื”. ืฉืœื•ืฉื” ืžื˜ื•ืคืœื™ื ื”ืชืœื•ื ื ื• ืขืœ ื›ืื‘ ืจืืฉ ืงืœ ืœืื—ืจ ื”ื”ืœื™ืš ื”ืจืืฉื•ื ื™ ืฉื”ื•ืงืœ ืœืื—ืจ ืืงืžื•ืœ 500 ืž"ื’. ืœืืฃ ืื—ื“ ืžื”ืžื˜ื•ืคืœื™ื ืœื ื”ื™ื™ืชื” ื“ืœืงืช ืื• ื–ื™ื”ื•ื. ืชื•ืฆืื•ืช ื‘ื“ื™ืงืช ืžืฉื™ื›ืช ื”ืฉื™ืขืจ ืžืจืื•ืช ื›ื™ ืžืกืคืจ ื”ืฉื™ืขืจ ืฉื ืฉืœืฃ ื™ืจื“ ื‘ืžืžื•ืฆืข ืฉืœ 65%.ย ืœืงืจืื™ืช ื”ืžื—ืงืจ ืœื—ืฅ ื›ืืŸ.

ืžื—ืงืจ PRP
Singhal et al. Efficacy of platelet-rich plasma in treatment of androgenic alopecia. Table 1

ื‘ืžื—ืงืจ ืžืฉื ืช 2014 ืฉืœ Cervelli et al. ืžืื™ื˜ืœื™ื”:

ื‘ืžื—ืงืจ ื–ื” ื‘ื“ืงื• ืžื˜ื•ืคืœื™ื ื’ื‘ืจื™ื ื‘ื’ื™ืœืื™ื 22-60, ืขื ื”ืชืงืจื—ื•ืช ื’ื‘ืจื™ืช ื˜ื™ืคื•ืกื™ืช. ืžื˜ื•ืคืœื™ื ื”ื ื•ื˜ืœื™ื ื˜ื™ืคื•ืœ ืœื”ืชืงืจื—ื•ืช ื˜ื•ืคื™ืงืœื™ (ืžื™ื ื•ืงืกื™ื“ื™ืœ ืœื“ื•ื’ืžื) ืื• ื˜ื™ืคื•ืœื™ ืกื™ืกื˜ืžื™ (ืคืจื•ืคืกื™ื” ืœื“ื•ื’ืžื) ื‘-12 ื”ื—ื•ื“ืฉื™ื ื”ืื—ืจื•ื ื™ื, ืœื ื”ื•ื›ื ืกื• ืœืžื—ืงืจ ื–ื”. ื‘ื ื•ืกืฃ, ืžืกืคืจื™ ื”ื˜ืกื™ื•ืช ื‘-PRP ืฉื”ืชืงื‘ืœื• ืžื›ืœ ื”ืžืฉืชืชืคื™ื ื ืกืคืจื• ื‘ืžื™ืงืจื•ืกืงื•ืค. ื”ืžื—ืงืจ ื”ื ื• ืžื—ืงืจ ืืงืจืื™, ื‘ื•ืฆืขื” ื‘ื“ื™ืงื” ืขื ืžื›ืฉื™ืจ TrichoScan ืขื ืžืขืจื™ืš ืดืขื™ื•ื•ืจืด (ื”ืื“ื ืฉืžื‘ืฆืข ืืช ื”ื”ืขืจื›ื” ืœืคื ื™ ื•ืื—ืจื™ ืœื ื™ื•ื“ืข ืžื™ ืงื™ื‘ืœ ื˜ื™ืคื•ืœ ื•ืžื™ ืงื™ื‘ืœ ืคืœืกื‘ื•), ื”ืžื—ืงืจ ื‘ื•ืฆืข ืขื ืคืœืกื‘ื• ื‘ื—ืฆื™ ืจืืฉ.ย 

ืคืจืžื˜ืจื™ ืฆืžื™ื—ืช ื”ืฉื™ืขืจ ื”ืฉื•ื ื™ื ืฉื ืžื“ื“ื• ืœืื—ืจ 3 ื—ื•ื“ืฉื™ื ืžื”ื˜ื™ืคื•ืœ ื”ืจืืฉื•ืŸ ื”ื•ืฉื•ื• ืœืžื—ืงืจ ื”ื‘ืกื™ืก ืœืคื ื™ ื”ื˜ื™ืคื•ืœ ื•ื‘ื™ืŸ ื”ื˜ื™ืคื•ืœ ื•ื”ื‘ื™ืงื•ืจืช. ื ืฆืคืชื” ืขืœื™ื™ื” ืžืžื•ืฆืขืช ื‘ืฆืคื™ืคื•ืช ื”ืฉืขืจ ื”ื›ื•ืœืœืช ืฉืœ 27.7 (ืžืกืคืจ ืฉืขืจื•ืช/ืกืž"ืจ) ื‘ื”ืฉื•ื•ืื” ืœื‘ืกื™ืก ืœืื—ืจ 3 ื—ื•ื“ืฉื™ื ื•ืื–ื•ืจ ื”ื‘ื™ืงื•ืจืช ื”ืฆื™ื’ ื™ืจื™ื“ื” ืžืžื•ืฆืขืช ืฉืœ 3.0 (ืžืกืคืจ ืฉืขืจื•ืช/ืกืž"ืจ).ย ืœืงืจืื™ืช ื”ืžื—ืงืจ ืœื—ืฅ ื›ืืŸ.

ืชื•ืฆืื•ืช ืžื—ืงืจ ื‘ื ื•ืฉื PRP
Cervelli et al. The Effect of Autologous Activated Platelet Rich Plasma (AA-PRP) Injection on Pattern Hair Loss: Clinical and Histomorphometric Evaluation. Figure 9

ื‘ืžื—ืงืจ ืžืฉื ืช 2017 ืฉืœ Ferrando et al. ืžืกืคืจื“:

ื‘ืฉื•ื ื” ืžืฉืืจ ื”ืžื—ืงืจื™ื, ื”ืžื—ืงืจ ื”ื–ื” ื”ืชืžืงื“ ื‘ืžื˜ื•ืคืœื™ื ืฉื‘ื”ื ื”ื˜ื™ืคื•ืœ ื”ืฉืžืจื ื™ ืœื ืฆืœื—. ื”ืžื—ืงืจ ื‘ื“ืง ืืช ื”ืฉืคืขืช ื˜ื™ืคื•ืœ PRP ืขืœ 78 ื’ื‘ืจื™ื ื•ื ืฉื™ื ืขื ื”ืชืงืจื—ื•ืช ื˜ื™ืคื•ืกื™ืช ื‘ื“ืจื’ื•ืช ื‘ื™ืŸ 2 ืขื“ 4 ืืฉืจ ืžื˜ื•ืคืœื™ื ื‘ืžื™ื ื•ืงืกื™ื“ื™ืœ ืื• ืคืจื•ืคืกื™ื” ืœืžืฉืš ื™ื•ืชืจ ืžืฉื ื” ืœืœื ืฉื™ืคื•ืจ. 3 ื˜ื™ืคื•ืœื™ PRP ื‘ื•ืฆืขื• ื‘ืžืจื•ื•ื— ืฉืœ ื—ื•ื“ืฉ ื•ืขื•ื“ 3 ื˜ื™ืคื•ืœื™ื ื‘ืžืจื•ื•ื— ืฉืœ ื—ื•ื“ืฉื™ื™ื. ื‘ืžื—ืงืจ ื ืžืฆื ืฉ-71.4% ืžื”ื’ื‘ืจื™ื ื•-73.4% ืžื”ื ืฉื™ื ื”ืฆื™ื’ื• ืฉื™ืคื•ืจ ื‘ืžืฆื‘ื ืœืื—ืจ ื”ื˜ื™ืคื•ืœื™ื.ย ืœืงืจืื™ืช ื”ืžื—ืงืจ ืœื—ืฅ ื›ืืŸ.

ืชื•ืฆืื•ืช ื ืฉื™ื•ืช ืฉืœ ืžื—ืงืจ ืขืœ PRP
Ferrando et al. A Proposal of an Effective Platelet-rich Plasma Protocol for the Treatment of Androgenetic Alopecia. Figure 4

ื‘ืžื—ืงืจ ืžืฉื ืช 2015 ืฉืœ Gentile et al. ืžืื™ื˜ืœื™ื”:

ื‘ื•ืฆืข ืžื—ืงืจ ืืงืจืื™, ืขื™ื•ื•ืจ ืžืขืจื™ืš, ืžื‘ื•ืงืจ ืคืœืฆื‘ื• ื—ืฆื™ ืจืืฉ. ื”ืฉื•ื•ืื” ื‘ื•ืฆืขื” ื‘ืขื–ืจืช ื˜ืจื™ื›ื•ื’ืจืžื•ืช ืžืžื•ื—ืฉื‘ื•ืช, ืฆืžื™ื—ืช ืฉื™ืขืจ ืžื—ื“ืฉ ืขื PRP ืœืขื•ืžืช ืคืœืฆื‘ื•. ื”ื‘ื˜ื™ื—ื•ืช ื•ื”ื™ืขื™ืœื•ืช ื”ืงืœื™ื ื™ืช ืฉืœ ื–ืจื™ืงื•ืช PRP ืื•ื˜ื•ืœื•ื’ื™ื•ืช ืœื ืฉื™ืจืช ืฉื™ืขืจ ื‘ื“ืคื•ืก ื ื—ืงืจื•. PRP, ืฉื”ื•ื›ืŸ ืžื ืคื— ืงื˜ืŸ ืฉืœ ื“ื, ื”ื•ื–ืจืง ืœืžื—ืฆื™ืช ืžื”ืงืจืงืคืช ืฉืœ ื”ืžื˜ื•ืคืœื™ื ืฉื ื‘ื—ืจื• ืขื ื ืฉื™ืจืช ืฉื™ืขืจ. ื”ื—ืฆื™ ื”ืฉื ื™ ื˜ื•ืคืœ ื‘ืคืœืกื‘ื•. ืฉืœื•ืฉื” ื˜ื™ืคื•ืœื™ื ื ื™ืชื ื• ืœื›ืœ ืžื˜ื•ืคืœ ื‘ืžืจื•ื•ื—ื™ื ืฉืœ 30 ื™ื•ื. ื ืงื•ื“ื•ืช ื”ืกื™ื•ื ื”ื™ื• ืฆืžื™ื—ื” ืžื—ื•ื“ืฉืช ืฉืœ ืฉื™ืขืจ, ื ื™ื•ื•ืŸ ืฉื™ืขืจ ื›ืคื™ ืฉื ืžื“ื“ ืขืœ ื™ื“ื™ ื“ืจืžื•ืกืงื•ืคื™ื”, ืชื—ื•ืฉืช ืฆืจื™ื‘ื” ืื• ื’ื™ืจื•ื“, ื•ืฉื’ืฉื•ื’ ืชืื™ื ื›ืคื™ ืฉื ืžื“ื“ ืขืœ ื™ื“ื™ ื”ืขืจื›ืช Ki67. ื”ืžื˜ื•ืคืœื™ื ื”ื™ื• ื‘ืžืขืงื‘ ื‘ืžืฉืš ืฉื ืชื™ื™ื. ืžืชื•ืš 23 ื”ืžื˜ื•ืคืœื™ื ืฉื ืจืฉืžื•, 3 ืœื ื ื›ืœืœื•. ื‘ืชื•ื 3 ืžื—ื–ื•ืจื™ ื”ื˜ื™ืคื•ืœ, ื”ืžื˜ื•ืคืœื™ื ื”ืฆื™ื’ื• ืฉื™ืคื•ืจ ืงืœื™ื ื™ ื‘ืžืกืคืจ ื”ืฉืขืจื•ืช ื”ืžืžื•ืฆืข, ืขื ืขืœื™ื™ื” ืžืžื•ืฆืขืช ืฉืœ 33.6 ืฉืขืจื•ืช ื‘ืื–ื•ืจ ื”ืžื˜ืจื”, ื•ืขืœื™ื™ื” ืžืžื•ืฆืขืช ื‘ืฆืคื™ืคื•ืช ื”ืฉื™ืขืจ ื”ื›ื•ืœืœืช ืฉืœ 45.9 ืฉืขืจื•ืช ืœืกืž"ืจ ื‘ื”ืฉื•ื•ืื” ืœืขืจื›ื™ ื”ื‘ืกื™ืก. ืœื ื ืจืฉืžื• ืชื•ืคืขื•ืช ืœื•ื•ืื™ ื‘ืžื”ืœืš ื”ื˜ื™ืคื•ืœ. ื”ืขืจื›ื” ืžื™ืงืจื•ืกืงื•ืคื™ืช ื”ืจืืชื” ืขืœื™ื™ื” ื‘ืขื•ื‘ื™ ื”ืืคื™ื“ืจืžื™ืก ื•ื‘ืžืกืคืจ ื–ืงื™ืงื™ ื”ืฉื™ืขืจ ืฉื‘ื•ืขื™ื™ื ืœืื—ืจ ื˜ื™ืคื•ืœ ื”-PRP ื”ืื—ืจื•ืŸ ื‘ื”ืฉื•ื•ืื” ืœืขืจืš ื”ื‘ืกื™ืกื™. ื›ืžื• ื›ืŸ, ืจืื™ื ื• ืขืœื™ื™ื” ืฉืœ Ki67+ keratinocytes ื‘ืืคื™ื“ืจืžื™ืก ื•ื‘ืชืื™ ื‘ืœื™ื˜ื” ื–ืงื™ืงื™ ืฉื™ืขืจ, ื•ืขืœื™ื™ื” ืงืœื” ืฉืœ ื›ืœื™ ื“ื ืงื˜ื ื™ื ืกื‘ื™ื‘ ื–ืงื™ืงื™ ืฉื™ืขืจ ื‘ืขื•ืจ ื”ืžื˜ื•ืคืœ ื‘ื”ืฉื•ื•ืื” ืœืงื• ื”ื‘ืกื™ืก. ื”ื™ืฉื ื•ืช ืฉืœ ื”ืชืงืจื—ื•ืช ืื ื“ืจื•ื’ื ื™ืช ืœื ื”ื•ืขืจื›ื” ื‘ื›ืœ ื”ื—ื•ืœื™ื ืขื“ 12 ื—ื•ื“ืฉื™ื ืœืื—ืจ ื”ื˜ื™ืคื•ืœ ื”ืื—ืจื•ืŸ. ืœืื—ืจ 12 ื—ื•ื“ืฉื™ื, 4 ืžื˜ื•ืคืœื™ื ื“ื™ื•ื•ื—ื• ืขืœ ื ืฉื™ืจืช ืฉื™ืขืจ ืžืชืงื“ืžืช; ื–ื” ื”ื™ื” ื‘ืจื•ืจ ื™ื•ืชืจ 16 ื—ื•ื“ืฉื™ื ืœืื—ืจ ื”ื˜ื™ืคื•ืœ ื”ืื—ืจื•ืŸ. ืืจื‘ืขืช ื”ื—ื•ืœื™ื ื”ืœืœื• ื˜ื•ืคืœื• ืžื—ื“ืฉ. ื”ื ืชื•ื ื™ื ืžื“ื’ื™ืฉื™ื ื‘ื‘ื™ืจื•ืจ ืืช ื”ื”ืฉืคืขื•ืช ื”ื—ื™ื•ื‘ื™ื•ืช ืฉืœ ื–ืจื™ืงื•ืช PRP ืขืœ ื ืฉื™ืจืช ืฉื™ืขืจ ื’ื‘ืจื™ืช ื•ื”ื™ืขื“ืจ ืชื•ืคืขื•ืช ืœื•ื•ืื™ ืžืฉืžืขื•ืชื™ื•ืช. PRP ืขืฉื•ื™ ืœืฉืžืฉ ืืคืฉืจื•ืช ื˜ื™ืคื•ืœ ื‘ื˜ื•ื—ื” ื•ื™ืขื™ืœื” ื ื’ื“ ื ืฉื™ืจืช ืฉื™ืขืจ.ย ืœืงืจืื™ืช ื”ืžื—ืงืจ ืœื—ืฅ ื›ืืŸ.

ืชื•ืฆืื•ืช ืžื—ืงืจ PRP
Gentile et al. The Effect of Platelet-Rich Plasma in Hair Regrowth: A Randomized Placebo-Controlled Trial. Figure 2

ื‘ืžื—ืงืจ ืžืฉื ืช 2011 ืฉืœ Takikawa et al. ืžื™ืคืŸ:

ื”ืžืฉืชืชืคื™ื ื”ื™ื• 26 ืžืชื ื“ื‘ื™ื ืขื ืฉื™ืขืจ ื“ืง ืฉืงื™ื‘ืœื• ื—ืžื™ืฉื” ื˜ื™ืคื•ืœื™ื ืžืงื•ืžื™ื™ื ืฉืœ 3 ืž"ืœ PRP (ืงื‘ื•ืฆืช ื”ืžื—ืงืจ, 13 ืžืฉืชืชืคื™ื) ื•ืงื‘ื•ืฆื” ืฉื ื™ื” ืฉืงื™ื‘ืœื” ืกืœื™ื™ืŸ (ื‘ื™ืงื•ืจืช, 13 ืžืฉืชืชืคื™ื) ื‘ืžืจื•ื•ื—ื™ื ืฉืœ 2-3 ืฉื‘ื•ืขื•ืช ื•ื”ื•ืขืจื›ื• ืขื‘ื•ืจ 12 ืฉื‘ื•ืขื•ืช. ืื–ื•ืจื™ื ืฉื”ื•ื–ืจืงื• ื›ืœืœื• ืืชืจื™ื ื—ื–ื™ืชื™ื™ื ืื• ืคืจื™ืื˜ืœื™ื™ื ืขื ืฉื™ืขืจ ื“ืง. ืฆื•ืœืžื• ืื–ื•ืจื™ ื ื™ืกื•ื™ ื•ื‘ืงืจื”. ืžืฉืชืชืคื™ื ืืฉืจ ื”ื‘ื™ืขื• ื”ืกื›ืžื” ืœื›ืš, ืขื‘ืจื• ื‘ื™ื•ืคืกื™ื•ืช ืœื‘ื“ื™ืงื” ื”ื™ืกื˜ื•ืœื•ื’ื™ืช. ื”ื‘ื“ืœื™ื ืžืฉืžืขื•ืชื™ื™ื ื ืจืื• ื‘ื—ืชืš ืฉื™ืขืจ ืืš ืœื ื‘ืžืกืคืจ ื”ืฉื™ืขืจื•ืช. ืžืžืฆืื™ื ืžื™ืงืจื•ืกืงื•ืคื™ื™ื ื”ืจืื• ืืคื™ืชืœ ืžืขื•ื‘ื”, ืฉื’ืฉื•ื’ ืฉืœ ืกื™ื‘ื™ ืงื•ืœื’ืŸ ื•ืคื™ื‘ืจื•ื‘ืœืกื˜ื™ื ื•ื”ื’ื“ืœืช ื›ืœื™ ื”ื“ื ืกื‘ื™ื‘ ื”ื–ืงื™ืงื™ื.ย ืœืงืจืื™ืช ื”ืžื—ืงืจ ืœื—ืฅ ื›ืืŸ.

ื‘ืžื—ืงืจ ืžืฉื ืช 2014 ืฉืœ Schiavone et al. ืžืื™ื˜ืœื™ื”:

ืฉื™ืคื•ืจ ืžืกื•ื™ื ื ืฆืคื” ื‘ื›ืœ ื”ืžื˜ื•ืคืœื™ื ืขืœ ื™ื“ื™ ืžืขืจื™ืš ืื—ื“ ื•ื‘-62 ืขืœ ื™ื“ื™ ื”ืื—ืจ. ื”ืฉื™ื ื•ื™ ื”ืžืžื•ืฆืข ื‘ื“ื™ืจื•ื’ ื”ืงืœื™ื ื™ ื”ื™ื” 3.2 ื•-3.9, ืฉื™ืขื•ืจ ื”ืžื˜ื•ืคืœื™ื ืฉื”ื’ื™ืขื• ืœื”ื‘ื“ืœ ื‘ืขืœ ื—ืฉื™ื‘ื•ืช ืงืœื™ื ื™ืช ื”ื™ื” 40.6% ื•-54.7%, ืœืคื™ 2 ื”ืžืขืจื™ื›ื™ื, ื‘ื”ืชืืžื”.ย ืœืงืจืื™ืช ื”ืžื—ืงืจ ืœื—ืฅ ื›ืืŸ.

ืชื•ืฆืื•ืช ืžื—ืงืจ ืขืœ PRP - ืืฉื” ื‘ืžืฆื‘ ืžืชืงื“ื
Ferrando et al. A Proposal of an Effective Platelet-rich Plasma Protocol for the Treatment of Androgenetic Alopecia. Figure 5

ื‘ืžื—ืงืจื™ื ื”ื ืดืœ ื ื™ืชืŸ ืœืจืื•ืช ื›ื™ ื”ื˜ื™ืคื•ืœ ื™ืขื™ืœ ื•ืžื‘ื•ืกืก ืžื—ืงืจื™ืช, ืืš ืขื ื–ืืช, ื—ื™ื™ื‘ื™ื ืœืฉื™ื ืœื‘ ืฉื‘ื›ืœ ืื—ื“ ืžื”ืžื—ืงืจื™ื, ื”ื™ื• ื’ื ืžื™ืขื•ื˜ ืฉืœ ื ื‘ื“ืงื™ื ืฉืขืœื™ื”ื ื”ื˜ื™ืคื•ืœ ื”ืฉืคื™ืข ืžืขื˜ ืื• ืœื ืกื™ื™ืข ืœื”ื. ืžื™ืฉื”ื• ื”ื‘ื˜ื™ื— ืœื›ื ื˜ื™ืคื•ืœ ืขื 100% ื”ืฆืœื—ื” ? ื›ื“ืื™ ืฉืชืชื—ื™ืœื• ืœื—ืฉื•ื“ ! ืื™ืŸ 100% ื‘ืจืคื•ืื”.

ย ืื ื• ื‘-PRPclinic ื ืฉืžื— ืœื”ืขื ื™ืง ืœืš ื˜ื™ืคื•ืœ ืืฉืจ ืžื‘ื•ืกืก ืขืœ ืžื—ืงืจื™ื ื•ื ืขืฉื” ื”ื›ืœ ื›ืš ืฉืชื•ืฉื’ ื”ืชื•ืฆืื” ื”ืžื™ื˜ื‘ื™ืช ืœืฉื™ืงื•ื ื”ืฉื™ืขืจ ืฉืœืš.

ืจื•ืฆื” ืคืจื˜ื™ื ื ื•ืกืคื™ื ? 058-4664664